Scarica l'app Stockscreener
8.10
2.66%
0.21
Dopo l'orario di chiusura:
8.10
Precedente Chiudi:
$7.89
Aprire:
$7.82
Volume 24 ore:
342.08K
Relative Volume:
0.77
Capitalizzazione di mercato:
$452.89M
Reddito:
-
Utile/perdita netta:
$-153.16M
Rapporto P/E:
-2.1951
EPS:
-3.69
Flusso di cassa netto:
$-134.48M
1 W Prestazione:
+4.65%
1M Prestazione:
-4.93%
6M Prestazione:
-50.00%
1 anno Prestazione:
-48.28%
Intervallo 1D:
$7.82
$8.39
Intervallo di 1 settimana:
$7.38
$8.39
Portata 52W:
$6.85
$30.19
Cullinan Therapeutics Inc Stock (CGEM) Company Profile
Nome
Cullinan Therapeutics Inc
Settore
Industria
Telefono
617-410-4650
Indirizzo
ONE MAIN STREET, CAMBRIDGE
Confronta CGEM con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
CGEM
Cullinan Therapeutics Inc
|
8.10 | 452.89M | 0 | -153.16M | -134.48M | -3.69 |
|
VRTX
Vertex Pharmaceuticals Inc
|
477.52 | 127.47B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
561.49 | 62.43B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
595.70 | 37.03B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
232.75 | 31.06B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
229.22 | 26.16B | 3.81B | -644.79M | -669.77M | -6.24 |
Cullinan Therapeutics Inc Stock (CGEM) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-10-24 | Iniziato | UBS | Buy |
| 2024-05-01 | Iniziato | Stifel | Buy |
| 2024-04-15 | Iniziato | William Blair | Outperform |
| 2024-02-15 | Iniziato | Wedbush | Outperform |
| 2023-06-15 | Iniziato | TD Cowen | Outperform |
| 2022-11-21 | Iniziato | BTIG Research | Buy |
| 2021-04-27 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2021-02-02 | Iniziato | Evercore ISI | Outperform |
| 2021-02-02 | Iniziato | Morgan Stanley | Equal-Weight |
| 2021-02-02 | Iniziato | SVB Leerink | Outperform |
| 2021-02-01 | Iniziato | H.C. Wainwright | Buy |
Mostra tutto
Cullinan Therapeutics Inc Borsa (CGEM) Ultime notizie
Geode Capital Management LLC Acquires 6,220 Shares of Cullinan Therapeutics, Inc. (NASDAQ:CGEM) - Defense World
Federated Hermes Inc. Boosts Stock Position in Cullinan Therapeutics, Inc. (NASDAQ:CGEM) - Defense World
HC Wainwright Reiterates “Buy” Rating for Cullinan Therapeutics (NASDAQ:CGEM) - Defense World
Cullinan Therapeutics receives EMA approval for rheumatoid arthritis drug trial - Yahoo Finance
EMA greenlights Cullinan’s arthritis drug trial in Europe By Investing.com - Investing.com South Africa
Cullinan gets EU nod to begin testing CLN-978 in rheumatoid arthritis - Seeking Alpha
Cullinan Therapeutics Receives Approval from European Medicines - GuruFocus
Cullinan Therapeutics (CGEM) Receives EMA Approval for Rheumatoid Arthritis Trial | CGEM Stock News - GuruFocus
EMA greenlights Cullinan’s arthritis drug trial in Europe - Investing.com
Cullinan Therapeutics Receives Approval from European Medicines Agency to Initiate Phase 1 Trial of CLN-978, a Bispecific CD19 T Cell Engager Administered Subcutaneously, in Patients with Rheumatoid Arthritis - GlobeNewswire
Cullinan Therapeutics Receives Approval from European Medicines Agency to Initiate Phase 1 Trial of CLN-978, a Bispecific CD19 T Cell Engager Administered Subcutaneously, in Patients with Rheumatoid Arthritis - GlobeNewswire Inc.
Vanguard Group Inc. Reduces Position in Cullinan Therapeutics, Inc. (NASDAQ:CGEM) - Defense World
Wellington Management Group LLP Has $1.62 Million Stock Position in Cullinan Therapeutics, Inc. (NASDAQ:CGEM) - Defense World
KLP Kapitalforvaltning AS Purchases Shares of 6,800 Cullinan Therapeutics, Inc. (NASDAQ:CGEM) - Defense World
Cullinan Therapeutics, Inc. (NASDAQ:CGEM) Shares Acquired by American Century Companies Inc. - Defense World
Corebridge Financial Inc. Sells 1,941 Shares of Cullinan Therapeutics, Inc. (NASDAQ:CGEM) - Defense World
Cullinan Therapeutics: Attractive Pipeline Progress, But We Will Wait For Complete Phase 2b Data - Seeking Alpha
Cullinan Therapeutics, Inc. (NASDAQ:CGEM) Receives Average Rating of “Buy” from Analysts - Defense World
Cullinan Therapeutics, Inc. (NASDAQ:CGEM) Shares Sold by Swiss National Bank - Defense World
Charles Schwab Investment Management Inc. Has $5.25 Million Stock Holdings in Cullinan Therapeutics, Inc. (NASDAQ:CGEM) - Defense World
20,273 Shares in Cullinan Therapeutics, Inc. (NASDAQ:CGEM) Purchased by Connor Clark & Lunn Investment Management Ltd. - Defense World
Cullinan Therapeutics (NASDAQ:CGEM) Shares Down 2.1% – Time to Sell? - Defense World
EGFR Non-Small Cell Lung Cancer Clinical and Non-Clinical - openPR
Morgan Stanley Reaffirms Overweight Rating for Cullinan Therapeutics (NASDAQ:CGEM) - Defense World
Cullinan Therapeutics, Inc. (NASDAQ:CGEM) Receives Average Recommendation of “Buy” from Analysts - Defense World
Cullinan Therapeutics: Promising Pipeline and Upcoming Catalysts Justify Buy Rating - TipRanks
Rhumbline Advisers Raises Position in Cullinan Therapeutics, Inc. (NASDAQ:CGEM) - Defense World
New York State Common Retirement Fund Buys 3,200 Shares of Cullinan Therapeutics, Inc. (NASDAQ:CGEM) - Defense World
Cullinan Therapeutics (CGEM) to Release Quarterly Earnings on Thursday - Defense World
Cullinan Therapeutics (NASDAQ:CGEM) Given "Buy" Rating at HC Wainwright - MarketBeat
Cullinan Therapeutics (NASDAQ:CGEM) Announces Earnings Results - MarketBeat
Q1 Earnings Estimate for CGEM Issued By William Blair - Defense World
Cullinan Therapeutics’ (CGEM) “Buy” Rating Reiterated at HC Wainwright - Defense World
Cullinan Therapeutics Inc (CGEM) Reports Q4 2024 Net Loss of $47 - GuruFocus.com
Pre-market Movers: BTAI, VRPX, DCGO, NBY... - RTTNews
Cullinan Therapeutics: Q4 Earnings Snapshot - The Pioneer
Cullinan Therapeutics’ chief medical officer sells $41,754 in stock - Investing.com India
Cullinan Therapeutics Reports 2024 Financial Results and Updates - TipRanks
Cullinan Therapeutics’ chief medical officer sells $41,754 in stock By Investing.com - Investing.com Canada
Cullinan Therapeutics CEO sells $106,872 in stock By Investing.com - Investing.com Canada
Cullinan Therapeutics CEO sells $106,872 in stock - Investing.com India
Cullinan Therapeutics' chief medical officer sells $41,754 in stock - Investing.com
Cullinan Therapeutics Reports Phase 1 Study Updates and Financial Results for Q4 2024 - Nasdaq
Cullinan Therapeutics, Inc. SEC 10-K Report - TradingView
Cullinan Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2024 Financial Results - GlobeNewswire
Financial Review: Cullinan Therapeutics (NASDAQ:CGEM) and Adaptimmune Therapeutics (NASDAQ:ADAP) - Defense World
Cullinan Therapeutics to Participate in Upcoming Investor Conferences - The Manila Times
Exclusive Access: Cullinan Therapeutics Leadership Reveals Strategy at Elite Healthcare Forums - StockTitan
Prepare Yourself for Liftoff: Cullinan Therapeutics Inc (CGEM) - SETE News
Cullinan Therapeutics Inc Azioni (CGEM) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.15%
4.32%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):